The Texas Liver Institute
Lisa Pedicone has a diverse work experience in the healthcare industry. Lisa currently holds the position of Vice President, Clinical Affairs and Business Development at R&R Strategies, Inc. Lisa also has experience as the Director of Education, CRO Services and Strategic Marketing at The Texas Liver Institute. Previously, Lisa has worked as the Executive Vice President, Clinical Affairs at Focus Medical Communications and as the Executive Global Director, Scientific Affairs-Hepatitis and Vice President/Global Franchise Medical Director-CV/Diabetes/ID, Medical Affairs at Merck. Lisa has also held roles as the Senior Director, Clinical Research, Hepatology at Schering Plough. In addition, Lisa has experience in different roles at Schering Plough, including Senior Director, Clinical Research, Antifungals; Associate Director/Director, Clinical Research, CNS/Obesity; and Manager, Regulatory Affairs, CV/CNS.
Lisa Pedicone received their BA degree in Biochemistry from Smith College, where they studied from 1985 to 1989. Lisa then pursued further education at the University of Pennsylvania School of Medicine, where they obtained their PhD in Pharmacology from 1989 to 1996.
This person is not in any teams
This person is not in any offices
The Texas Liver Institute
The Texas Liver Institute is a one-of-a-kind facility with liver experts, healthcare providers and ancillary services that provide the standard of excellence in evaluation and treatment of liver diseases including: • Autoimmune Liver Diseases • Viral Hepatitis • Fatty Liver • Cirrhosis and Portal Hypertension • Liver Cancer • End Stage Liver Disease and Transplantation Known for cutting-edge and innovative research, patients seek us out for advanced liver care and access to the large array of research opportunities at The Texas Liver Institute. Our modern 22,000 square foot research and clinical facility includes services such as: • Outpatient and Inpatient Clinical Services • CLIA and CAP Certified Lab • Non-Invasive Fibrosis Assessment and Treatment • Phase 1 Inpatient Unit • Phase 2/3 Clinical Trials